HPTN Publications
Looking to submit your manuscript for review?
Submit your manuscript to the Manuscript Review Committee.
Filter publications by:
Sugarman J, Trumble I, Hamilton EL, Sarasvita R, Dumchev K, Viet H, Hoffman I, Miller W, Hanscom B . Reported Participation Benefits in International Hiv Prevention Research with People Who Inject Drugs. [HPTN 074]. Ethics Hum Res. , 41: 28-34
2019
Ethics Hum Res
HPTN 074
Susan H Eshleman, Estelle Piwowar-Manning, Mariya V. Sivay, Barbara Debevec, Stephanie Veater, Laura McKinstry, Linda Gail Bekker, Sharon Mannheimer, Robert M. Grant, Margaret A. Chesney, Thomas J. Coates, Beryl A. Koblin, Jessica M. Fogel, Eshleman SH, Piwowar-Manning E, Sivay MV, Debevec B, Veater S, McKinstry L, Bekker LG, Mannheimer S, Grant RM, Chesney MA, Coates TJ, Koblin BA, Fogel JM . Performance of the BioPlex 2200 HIV Ag-Ab assay for identifying acute HIV infection. J Clin Virol. 2018, 99-100: 67-70
2018
J Clin Virol
HPTN 067
T Gamble, B Branson, D Donnell, HI Hall, G King, B Cutler, S Hader, D Burns, J Leider, AF Wood, KG Volpp, WM El-Sadr . Design of the HPTN 065 (TLC-Plus) Study: A Study to Evaluate the Feasibility of an Enhanced Test, Link-to-Care, Plus Treat Approach for HIV Prevention in the United States. Clin Trials. 2017, 14: 322-332
2017
Clin Trials
HPTN 065
Taggart T, Mayer KH, Vermund SH, Huang S, Hayashi K, Ransome Y . Interaction of Religion/Spirituality With Internalized HIV Stigma, Depression, Alcohol Use, and Sexual Risk Among Black Men Who Have Sex With Men: The 6 City HPTN 061 Study. J Acquir Immune Defic Syndr. 2021, 87: e188-e197
2021
J Acquir Immune Defic Syndr
HPTN 061
Takuva S, Karuna ST, Juraska M, Rudnicki E, Edupuganti S, Anderson M, De La Grecca R, Gaudinski MR, Sehurutshi A, Orrell C, Naidoo L, Valencia J, Villela LM, Walsh SR, Andrew P, Karg C, Randhawa A, Hural J, Gomez Lorenzo MM, Burns DN, Ledgerwood J, Mascola JR, Cohen M, Corey L, Mngadi K, Mgodi NM, HVTN 703/HPTN 081 and HVTN 704/HPTN 085 Study Teams. . Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials.. J Acquir Immune Defic Syndr. 2022, 89: 405-413
2022
J Acquir Immune Defic Syndr
HVTN 703/HPTN 081
Tedrow VA, Zelaya CE, Kennedy CE, Morin SF, Khumalo-Sakutukwa G, Sweat MD, Celentano DD . No "Magic Bullet": Exploring community mobilization strategies used in a multi-site community based randomized controlled trial: Project Accept (HPTN 043). AIDS Behav. 2012, 16: 1217-26
2012
AIDS Behav
HPTN 043
Telisinghe L, Floyd S, MacLeod D, Schaap A, Dunbar R, Bwalya J, Bell-Mandla N, Piwowar-Manning E, Donnell D, Shaunaube K, Bock P, Fidler S, Hayes RJ, Ayles HM; HPTN 071 (PopART) study team . Incidence of self-reported tuberculosis treatment with community-wide universal testing and treatment for HIV and tuberculosis screening in Zambia and South Africa: A planned analysis of the HPTN 071 (PopART) cluster-randomised trial. PLoS Med. 2024, 21: e1004393
2024
PLoS Med
HPTN 071
Theodore DA, Neradilek M, Gillespie K, Edupuganti S, Hinojosa JC, Lama JR, De La Grecca R, Wu YH, Davis A, Mangini D, Andrew P, Marovich MA, Zwerski S, Broder G, Andrasik MP, Castor D, Roxby AC, Cohen M, Huang Y, Karuna ST, Sobieszczyk ME. . Brief Report: Associations Between Gender and Solicited Adverse Events After Passive Infusion of VRC01 or Placebo in HVTN 704/HPTN 085. J Acquir Immune Defic Syndr. 2025, 98: 340-345
2025
J Acquir Immune Defic Syndr
HVTN 704/HPTN 085